


# Author's Accepted Manuscript

Down Syndrome, Rasopathies, and Other Rare Syndromes

Christian P. Kratz, Shai Izraeli



PII: S0037-1963(17)30053-7

DOI: <http://dx.doi.org/10.1053/j.seminhematol.2017.04.008>

Reference: YSHEM50915

To appear in: *Seminars in Hematology*

Cite this article as: Christian P. Kratz and Shai Izraeli, Down Syndrome, Rasopathies, and Other Rare Syndromes, *Seminars in Hematology*, <http://dx.doi.org/10.1053/j.seminhematol.2017.04.008>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**DOWN SYNDROME, RASOPATHIES, AND OTHER RARE SYNDROMES**

Christian P. Kratz<sup>1</sup> and Shai Izraeli<sup>2</sup>

<sup>1</sup>Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany

<sup>2</sup>The Genes, Development and Environment Institute for Pediatric Research, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Human Molecular Genetics and Biochemistry, Sackler Medical School, Tel Aviv University, Tel Aviv, Israel

**Correspondence to:** Prof. Dr. med. Christian Kratz, Hannover Medical School, Department of Pediatric Hematology and Oncology, Carl-Neuberg-Str. 1, 30625 Hannover, Germany, Tel. +49-511-532-6711, Fax +49-511-532- 9120, E-mail: [kratz.christian@mh-hannover.de](mailto:kratz.christian@mh-hannover.de)

**KEY MESSAGES**

1. Watch and wait in NS-related MPD and CBLS-related JMML, HSCT in patients with NF1-related JMML
2. The myeloid leukemias of DS are uniquely sensitive to Ara-C. Low-dose Ara-C may be needed for control of clinically advanced congenital transient myeloproliferative disorder.
3. Clinical studies examining the benefits of monitoring of GATA1s levels and prophylactic ARA-C therapy in infants with DS are warranted

Download English Version:

<https://daneshyari.com/en/article/5664424>

Download Persian Version:

<https://daneshyari.com/article/5664424>

[Daneshyari.com](https://daneshyari.com)